terlipressin has been researched along with Cancer of the Uterus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Haan, P; Haude, OCH; Overdijk, LE; Rademaker, BMP; Riezebos, RK; van Kesteren, PJM | 1 |
| Krizko, M | 1 |
1 trial(s) available for terlipressin and Cancer of the Uterus
| Article | Year |
|---|---|
The HYSTER study: the effect of intracervically administered terlipressin versus placebo on the number of gaseous emboli and fluid intravasation during hysteroscopic surgery: study protocol for a randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Drug Administration Routes; Echocardiography, Transesophageal; Embolism, Air; Female; Hemodynamics; Humans; Hysteroscopy; Middle Aged; Myoma; Netherlands; Randomized Controlled Trials as Topic; Risk Factors; Severity of Illness Index; Terlipressin; Time Factors; Treatment Outcome; Uterine Neoplasms; Young Adult | 2018 |
1 other study(ies) available for terlipressin and Cancer of the Uterus
| Article | Year |
|---|---|
[Possibilities of reducing blood loss during gynecologic operations with drugs].
Topics: Blood Loss, Surgical; Female; Gonadotropin-Releasing Hormone; Gynecologic Surgical Procedures; Humans; Leiomyoma; Lypressin; Terlipressin; Triptorelin Pamoate; Uterine Neoplasms; Vasoconstrictor Agents | 1999 |